- Home
- PNI vs TIL Comparison
PNI vs TIL Comparison
Compare PNI & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNI
- TIL
- Stock Information
- Founded
- PNI 2002
- TIL 2018
- Country
- PNI United States
- TIL United States
- Employees
- PNI N/A
- TIL N/A
- Industry
- PNI Trusts Except Educational Religious and Charitable
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- PNI Finance
- TIL Health Care
- Exchange
- PNI Nasdaq
- TIL Nasdaq
- Market Cap
- PNI 75.2M
- TIL 230.1M
- IPO Year
- PNI N/A
- TIL 2021
- Fundamental
- Price
- PNI $6.69
- TIL $24.49
- Analyst Decision
- PNI
- TIL Buy
- Analyst Count
- PNI 0
- TIL 5
- Target Price
- PNI N/A
- TIL $119.00
- AVG Volume (30 Days)
- PNI 26.4K
- TIL 310.3K
- Earning Date
- PNI 01-01-0001
- TIL 08-12-2025
- Dividend Yield
- PNI 4.76%
- TIL N/A
- EPS Growth
- PNI N/A
- TIL N/A
- EPS
- PNI N/A
- TIL N/A
- Revenue
- PNI N/A
- TIL N/A
- Revenue This Year
- PNI N/A
- TIL N/A
- Revenue Next Year
- PNI N/A
- TIL N/A
- P/E Ratio
- PNI N/A
- TIL N/A
- Revenue Growth
- PNI N/A
- TIL N/A
- 52 Week Low
- PNI $6.03
- TIL $9.70
- 52 Week High
- PNI $7.89
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- PNI 46.53
- TIL 47.69
- Support Level
- PNI $6.64
- TIL $21.80
- Resistance Level
- PNI $6.78
- TIL $26.91
- Average True Range (ATR)
- PNI 0.07
- TIL 3.52
- MACD
- PNI 0.01
- TIL -0.37
- Stochastic Oscillator
- PNI 35.71
- TIL 35.14
About PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.